MSBase Registry

⁦Fantastic presentation from ⁦@Benjamin_Trewin⁩ regarding his data on optimal therapeutic dosing of corticosteroids at #MOGAD onset delaying time to first relapse @ECTRIMS. Great audience discussions ⁦@syd_health⁩ ⁦@kids_research⁩ ⁦⁦⁦

#ECTRIMS2024 | Welcome to the 1st day of the 40th Congress of ECTRIMS! Thank YOU for being a vital part of this journey. 📽️ Watch MS experts Prof. Tobias Sejbæk, Prof. Jette Frederiksen, and Prof. Melinda Magyari (@melindamagyari), present today’s Daily Highlights. 👇 👇 👇

🚨 LIVE in 15 minutes! Join Scientific Session 1 on the revised diagnostic criteria w/ MS experts, incl. @xmontalban, @Marcello_Moccia, @DrWBRO, @kuchling_j, Fiorella Guido, @held_fr, chaired by @MarTintore & @Calabre04804429. 🔗 Join here: bit.ly/3AXBzOQ

MSBase is 20 years old!! and holds >110,000 patient records. Dedicated clinicians all over the world contributes data with >110 papers, many that have changed clinical practice. We are so grateful to all the supporters of our mission to improve the lives of people with #MS.

We are here and ready! Come and visit the MSBase team @ECTRIMS to get updates on 20 years of real-world data and evidence in #MS.

Your roadmap for Autoimmune Encephalitis. A useful slide being shared from our UK Childhood Neuroinflammatory Disorders meeting, put together by Dr Michael Eyre.

📢🔥Take note! Data from the massive @MSBase_Registry dataset shows that secondary and primary progressive MS disease differ in disease onset and course. This is super important to consider when studying disease modifying therapies. bit.ly/41i7x0w @izanne_roos

Fantastic catching up with friends &colleagues from the #BigMS data registries. Collectively, we manage ~300,000 patient records. “Harmonise the people, harmonise the data” @melindamagyari @dhorakova @TrojanoMaria @JiDrahota @VukusicS @MSBase_Registry @janhillert and many more!

Festive greetings and a joyous Christmas from the MSBase Management team, to our amazing MSBase Ops Team, SLG committees, Board and valued Members - wishing you all a safe and happy holiday season.

New published data @MonashCCS @Alfred_Research @HelmutButz @MSBase_Registry to support clinical decision making for patients with #MultipleSclerosis who need to switch #treatment to fully control their disease. Read more👇 monash.edu/medicine/news/…

Is HSCT really that good? This analysis at #ECTRIMS2022 (unrandomized) found HSCT is better than gilenya but similar in efficacy to ocrevus and tysabri (in relapses, disability progression), though improvement was more common with HSCT. ectrims2022.abstractserver.com/program/#/deta…

🌷Late breaking news at #ECTRIMS2022 @Iamsterdam Surprising or not? Propensity matched study of #HSCT versus #Natalizumab in #progressive #MS revealed no difference in efficacy. Early treatment best, applies to both💡

Izanne Roos presenting a non-inferiority study of ocrelizumab and rituximab on behalf of the @MSBase_Registry and the Danish registry

Kalincik @MSBase_Registry study: Propensity-matched #progressive #MS patients treated with AHSCT or natalizumab. No difference on relapse rates and disability progression. #ECTRIMS2022

Visiting the hard working team at the @MSBase_Registry booth at #ECTRIMS2022 thank you to Charlotte Sartori, Pam Farr, Rein Moore, and Dusko Stupar for their amazing work on the operations team making the magic happen 🙌🏻

Made it into the pregnancy session in time for a really relevant talk by Annika Anderson - low transfer of CD20 molecules into mature breast milk (ie post colostrum) with infant dose <1%

Excellent talk by @annalauralerede from at #ECTRIMS2022 presenting on the different ways MS can progress over time (using MS Register data) and how important online registers are for tracking disease long term 👍🏼

Dr. Nicole Bou Rjeily starting a great presentation at ECTRIMS. Strong scientist and future neurologist! @IntNatlWiMS @ECTRIMS

Chao Zhu representing @MSBase_Registry data @ECTRIMS #DMT efficacy. Congratulations to all MSBase investigators involved!

In prospectively reported cases, no increased risk of spontaneous pregnancy loss, preterm birth, ectopic pregnancy. Rate of elective abortion in exposed pregnancies decreasing over time. Very few major congenital abnormalities - with a similar distribution to expected